Drugs / PXS-4728
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05904717 | Nov 2023 → Sep 2024 overdue | REM sleep behavior disorder | Syntara | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PXS-4728 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05904717 ↗ |
| Route | Oral | “Mode: oral administration (PO)” NCT05904717 ↗ |